• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

颅内脑膜瘤中的端粒酶

Telomerase in intracranial meningiomas.

作者信息

Boldrini L, Pistolesi S, Gisfredi S, Ursino S, Lupi G, Caniglia M, Pingitore R, Basolo F, Parenti G, Fontanini G

机构信息

Department of Surgery, Division of Pathology, University of Pisa, Via Roma 57, I-56126 Pisa, Italy.

出版信息

Int J Mol Med. 2003 Dec;12(6):943-7. doi: 10.3892/ijmm.12.6.943.

DOI:10.3892/ijmm.12.6.943
PMID:14612971
Abstract

Telomere length maintenance is essential for tumorigenesis; most human tumors stabilize their chromosome ends via the activity of a specialized reverse transcriptase, telomerase, that uses the template region of the RNA moiety complementary to the TTAGGG repeat to synthesize one strand of telomeric DNA. Meningiomas are estimated to constitute between 13% and 26% of primary intracranial tumors. The aim of this study was to evaluate telomerase activity and its messenger expression in meningiomas in relation to their different histologic pattern and grade of cytonuclear atypies, which are associated with relapse, and consequently represent the most important parameter for the evaluation of the clinical behavior of this tumor. Telomerase activity was examined by the telomeric repeat amplification protocol (TRAP) assay in 32 meningiomas (26 typical and 6 atypical/anaplastic). Telomerase messenger expression (hTERT mRNA) was evaluated by reverse transcription-PCR analysis in the same group of tumors. Telomerase activity ranged from undetectable to low levels in 19/26 (73%) of typical meningiomas, while all the atypical/anaplastic meningiomas showed medium-high levels of activity (>3 TPG units, median value), (chi(2) test; p=0.001). The levels of telomerase in terms of its messenger level expression overlapped the activity; a significant association between telomerase activity and hTERT mRNA expression was also found (chi(2) test; p=0.01). Moreover, 2 atypical/anaplastic meningiomas of our series relapsed; in these samples we found high levels of telomerase, both in terms of activity and mRNA expression. Telomerase activity and its hTERT mRNA expression tended to increase as the histologic grading of intracranial tumors increased, suggesting a role of telomerase reactivation in the progression of these tumors. Moreover, our results indicate RT-PCR assay as a rapid tool to identify and quantify telomerase RNA in intracranial meningiomas as in other human tumor models.

摘要

端粒长度维持对于肿瘤发生至关重要;大多数人类肿瘤通过一种特殊的逆转录酶——端粒酶的活性来稳定其染色体末端,该酶利用与TTAGGG重复序列互补的RNA部分的模板区域来合成端粒DNA的一条链。据估计,脑膜瘤占原发性颅内肿瘤的13%至26%。本研究的目的是评估脑膜瘤中端粒酶活性及其信使表达,以及它们不同的组织学模式和细胞核异型性分级,这些与复发相关,因此是评估该肿瘤临床行为的最重要参数。通过端粒重复序列扩增协议(TRAP)分析检测了32例脑膜瘤(26例典型脑膜瘤和6例非典型/间变性脑膜瘤)的端粒酶活性。通过逆转录 - PCR分析评估了同一组肿瘤中端粒酶信使表达(hTERT mRNA)。19/26(73%)的典型脑膜瘤中端粒酶活性范围从检测不到到低水平,而所有非典型/间变性脑膜瘤均显示中高水平的活性(>3 TPG单位,中位数)(卡方检验;p = 0.001)。端粒酶在信使水平表达方面的水平与活性重叠;还发现端粒酶活性与hTERT mRNA表达之间存在显著关联(卡方检验;p = 0.01)。此外,我们系列中的2例非典型/间变性脑膜瘤复发;在这些样本中,我们在活性和mRNA表达方面均发现了高水平的端粒酶。随着颅内肿瘤组织学分级的增加,端粒酶活性及其hTERT mRNA表达趋于增加,表明端粒酶重新激活在这些肿瘤进展中起作用。此外,我们的结果表明,逆转录 - PCR分析是一种在颅内脑膜瘤中识别和定量端粒酶RNA的快速工具,如同在其他人类肿瘤模型中一样。

相似文献

1
Telomerase in intracranial meningiomas.颅内脑膜瘤中的端粒酶
Int J Mol Med. 2003 Dec;12(6):943-7. doi: 10.3892/ijmm.12.6.943.
2
Telomerase activity and expression of telomerase reverse transcriptase correlated with cell proliferation in meningiomas and malignant brain tumors in vivo.端粒酶活性及端粒酶逆转录酶的表达与体内脑膜瘤和恶性脑肿瘤中的细胞增殖相关。
Virchows Arch. 2001 Aug;439(2):176-84. doi: 10.1007/s004280100466.
3
Telomerase activity and expression of the telomerase catalytic subunit, hTERT, in meningioma progression.端粒酶活性及端粒酶催化亚基hTERT在脑膜瘤进展中的表达
J Neurosurg. 2000 May;92(5):832-40. doi: 10.3171/jns.2000.92.5.0832.
4
Telomerase activity and hTERT protein expression in meningiomas: an analysis in vivo versus in vitro.脑膜瘤中端粒酶活性与hTERT蛋白表达:体内与体外分析
Anticancer Res. 2006 May-Jun;26(3B):2295-300.
5
Relation between telomerase activity, hTERT and telomere length for intracranial tumours.颅内肿瘤中端粒酶活性、人端粒酶逆转录酶(hTERT)与端粒长度之间的关系。
Oncol Rep. 2007 Dec;18(6):1571-6. doi: 10.3892/or.18.6.1571.
6
Correlations between the expression of hTERT and α and β splice variants in human brain tumors.人脑中肿瘤中端粒酶逆转录酶(hTERT)与其α和β剪接变异体表达的相关性。
Adv Clin Exp Med. 2019 Apr;28(4):507-513. doi: 10.17219/acem/81934.
7
mRNA quantification and clinical evaluation of telomerase reverse transcriptase subunit (hTERT) in intracranial tumours of patients in the island of Crete.克里特岛患者颅内肿瘤中端粒酶逆转录酶亚基(hTERT)的mRNA定量及临床评估
Br J Cancer. 2005 Jul 11;93(1):152-8. doi: 10.1038/sj.bjc.6602642.
8
Implication of telomerase activity and alternations of telomere length in the histologic characteristics of intracranial meningiomas.端粒酶活性及端粒长度改变在颅内脑膜瘤组织学特征中的意义
Cancer. 2000 Nov 15;89(10):2092-8. doi: 10.1002/1097-0142(20001115)89:10<2092::aid-cncr9>3.0.co;2-n.
9
Telomerase activity and hTERT mRNA expression in glial tumors.神经胶质瘤中的端粒酶活性与人类端粒酶逆转录酶信使核糖核酸表达
Int J Oncol. 2006 Jun;28(6):1555-60. doi: 10.3892/ijo.28.6.1555.
10
Telomerase activity, TERT expression, hTERT promoter alterations, and alternative lengthening of the telomeres (ALT) in meningiomas - a systematic review.端粒酶活性、TERT 表达、hTERT 启动子改变以及脑膜瘤中的端粒非经典延长(ALT)——系统评价。
Neurosurg Rev. 2020 Jun;43(3):903-910. doi: 10.1007/s10143-019-01087-3. Epub 2019 Feb 20.

引用本文的文献

1
The causal relationship between genetically determined telomere length and meningiomas risk.基因决定的端粒长度与脑膜瘤风险之间的因果关系。
Front Neurol. 2023 Aug 24;14:1178404. doi: 10.3389/fneur.2023.1178404. eCollection 2023.
2
Preclinical Models of Meningioma.脑膜瘤的临床前模型。
Adv Exp Med Biol. 2023;1416:199-211. doi: 10.1007/978-3-031-29750-2_15.
3
: meningioma.脑膜瘤
Neurooncol Pract. 2016 Jun;3(2):120-134. doi: 10.1093/nop/npv063. Epub 2016 Jan 13.
4
TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma.TERT 启动子突变与脑膜瘤不良预后和细胞永生化有关。
Neuro Oncol. 2018 Nov 12;20(12):1584-1593. doi: 10.1093/neuonc/noy104.
5
hTERT promoter methylation in meningiomas and central nervous hemangiopericytomas.脑膜瘤和中枢神经系统血管外皮细胞瘤中的人端粒酶逆转录酶启动子甲基化
J Neurooncol. 2016 Oct;130(1):79-87. doi: 10.1007/s11060-016-2226-6. Epub 2016 Jul 27.
6
High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression.在经历恶性进展的脑膜瘤中,TERT启动子激活突变的发生率很高。
Brain Pathol. 2014 Mar;24(2):184-9. doi: 10.1111/bpa.12110. Epub 2013 Dec 23.
7
Meningioma mouse models.脑膜瘤小鼠模型。
J Neurooncol. 2010 Sep;99(3):325-31. doi: 10.1007/s11060-010-0331-5. Epub 2010 Aug 24.
8
Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth.利用人蛛网膜和脑膜瘤细胞培养系统对神经纤维瘤病2型进行建模:神经纤维瘤病2型基因沉默反映肿瘤生长的良性特征。
Neurobiol Dis. 2008 Feb;29(2):278-92. doi: 10.1016/j.nbd.2007.09.002. Epub 2007 Sep 19.
9
mRNA quantification and clinical evaluation of telomerase reverse transcriptase subunit (hTERT) in intracranial tumours of patients in the island of Crete.克里特岛患者颅内肿瘤中端粒酶逆转录酶亚基(hTERT)的mRNA定量及临床评估
Br J Cancer. 2005 Jul 11;93(1):152-8. doi: 10.1038/sj.bjc.6602642.